The present invention discloses and claims compounds of formula (I) and formula (II) ##STR00001## as inhibitors of human casein kinase I.epsilon., and methods of using the compounds of formula (I) and formula (II) for treating central nervous system diseases and disorders including mood disorders and sleep disorders. The R-group substituents are defined herein and pharmaceutical compositions comprising compounds of formula (I) or formula (II) are also disclosed and claimed.
Claims What is claimed is: 1. A compound selected from the group consisting of formula I and formula II, or a stereoisomer, an enantiomer, a racemate or a tautomer of said compound, or a pharmaceutically acceptable salt thereof, ##STR00050## wherein X is S or S(O).sub.n; R.sub.1 is H or C.sub.1-C.sub.6alkyl; R.sub.2 is NR.sub.5R.sub.6; R.sub.3 is aryl or heterocycle; R.sub.4 is C.sub.1-C.sub.6alkyl or halogen; R.sub.5 is H or C.sub.1-C.sub.6alkyl; R.sub.6 is H or C.sub.1-C.sub.6alkyl; R.sub.7 is CH.sub.2NR.sub.8R.sub.9 wherein R.sub.8 is H, C.sub.1-C.sub.10alkyl, C.sub.3-C.sub.8cycloalkyl, aryl, aryl(C.sub.1-C.sub.6alkyl), aryl(C.sub.2-C.sub.6alkenyl), diaryl(C.sub.2-C.sub.6alkenyl), heterocycle, heterocycle(C.sub.1-C.sub.6alkyl), heterocycle(C.sub.2-C.sub.6alkenyl), hydroxy(C.sub.1-C.sub.6alkyl), dihydroxy(C.sub.2-C.sub.6alkyl), acyl, C.sub.1-C.sub.6alkoxycarbonyl, aryl(C.sub.1-C.sub.6alkoxy)carbonyl, carbamoyl(C.sub.1-C.sub.6alkyl), or P; R.sub.9 is H, C.sub.1-C.sub.10alkyl, heterocycle(C.sub.1-C.sub.6alkyl) or heterocycle(C.sub.2-C.sub.6alkenyl); or R.sub.8 and R.sub.9 together with the nitrogen to which they are attached form a heterocycle; and wherein P is Gly, or L- or D-Ala, Val, Leu, Ile, Ser, Cys, Thr, Met, Pro, Phe, Tyr, Trp, His, Lys, Arg, Asp, Gly, Asn or Gln; m is 0, 1 or 2; and n is 1. 2. The compound selected from the group consisting of formula I and formula II as recited in claim 1 wherein X is S. 3. The compound selected from the group consisting of formula I and formula II as recited in claim 2 wherein R.sub.2 is NH.sub.2. 4. The compound selected from the group consisting of formula I and formula II as recited in claim 3 wherein m is 0 and R.sub.7 is CH.sub.2NR.sub.8R.sub.9. 5. The compound selected from the group consisting of formula I and formula II as recited in claim 4 wherein R.sub.1 is C.sub.1-C.sub.6alkyl. 6. The compound of formula I as recited in claim 5 wherein the compound is 1-methyl-5-methylaminomethyl-3-phenylsulfanyl-1H-indole-2-carboxylic acid amide. 7. The compound selected from the group consisting of formula I and formula II as recited in claim 4 wherein R.sub.1 is H. 8. The compound of formula I as recited in claim 7 wherein R.sub.8 is H, C.sub.1-C.sub.10alkyl, C.sub.3-C.sub.8cycloalkyl, hydroxy(C.sub.1-C.sub.6alkyl), dihydroxy(C.sub.2-C.sub.6alkyl) or C.sub.1-C.sub.6alkoxycarbonyl and R.sub.9 is H. 9. The compound of formula I as recited in claim 8 selected from the group consisting of: 5-aminomethyl-3-phenylsulfanyl-1H-indole-2-carboxylic acid amide, (2-carbamoyl-3-phenylsulfanyl-1H-indol-5-ylmethyl)-carbamic acid tert-butyl ester, 5-methylaminomethyl-3-phenylsulfanyl-1H-indole-2-carboxylic acid amide, 3-(3-chlorophenylsulfanyl)-5-methylaminomethyl-1H-indole-2-carboxylic acid amide, 3-(3-fluorophenylsulfanyl)-5-methylaminomethyl-1H-indole-2-carboxylic acid amide, 3-phenylsulfanyl-5-propylaminomethyl-1H-indole-2-carboxylic acid amide, 5-butylaminomethyl-3-phenylsulfanyl-1H-indole-2-carboxylic acid amide, 5-pentylaminomethyl-3-phenylsulfanyl-1H-indole-2-carboxylic acid amide, 5-heptylaminomethyl-3-phenylsulfanyl-1H-indole-2-carboxylic acid amide, 5-(bicyclo[2.2.1]hept-2-ylaminomethyl-3-phenylsulfanyl-1H-indole-2-carbox- ylic acid amide, 5-[(2-hydroxy-1-hydroxymethyl-1-methyl-ethylamino)methyl]-3-phenylsulfany- l-1H-indole-2-carboxylic acid amide, 5-[(2-hydroxy-1-methyl-ethylamino)methyl]-3-phenylsulfanyl-1H-indole-2-ca- rboxylic acid amide, 5-[(2,3-dihydroxypropylamino)methyl]-3-phenylsulfanyl-1H-indole-2-carboxy- lic acid amide, 5-ethylaminomethyl-3-phenylsulfanyl-1H-indole-2-carboxylic acid amide, 3-phenylsulfanyl-5-propylaminomethyl-1H-indole-2-carboxylic acid amide, and 5-(isopropylaminomethyl)-3-phenylsulfanyl-1H-indole-2-carboxylic acid amide. 10. The compound of formula I as recited in claim 7 wherein R.sub.8 is aryl, aryl(C.sub.1-C.sub.6alkyl), heterocycle or carbamoyl(C.sub.1-C.sub.6alkyl), and R.sub.9 is H. 11. The compound of formula I as recited in claim 10 selected from the group consisting of: 5-(benzylaminomethyl)-3-phenylsulfanyl-1H-indole-2-carboxylic acid amide, 3-phenylsulfanyl-5-(quinolin-6-ylaminomethyl)-1H-indole-2-carboxylic acid amide, 5-[(2-cyano-4,5-dimethoxyphenylamino)methyl]-3-phenylsulfanyl-1H-i- ndole-2-carboxylic acid amide, 3-phenylsulfanyl-5-[(3-trifluoromethyl-phenylamino)methyl]-1H-indole-2-ca- rboxylic acid amide, 5-[(1-carbamoylethylamino)methyl]-3-phenyl sulfanyl-1H-indole-2-carboxylic acid amide, 5-[(3-methoxyphenylamino)methyl]-3-phenylsulfanyl-1H-indole-2-carboxylic acid amide, 5-[(4-butylphenylamino)methyl]-3-phenylsulfanyl-1H-indole-2-carboxylic acid amide, and 5-[(2-fluorophenylamino)methyl]-3-phenylsulfanyl-1H-indole-2-carboxylic acid amide. 12. The compound of formula I as recited in claim 7 wherein R.sub.8 and R.sub.9 together with the nitrogen to which they are attached form a heterocycle. 13. The compound of formula I as recited in claim 12 selected from the group consisting of: 5-(4-hydroxymethylpiperidin-1-ylmethyl)-3-phenylsulfanyl-1H-indole-2-carb- oxylic acid amide, 5-morpholin-4-ylmethyl-3-phenylsulfanyl-1H-indole-2-carboxylic acid amide, 3-phenylsulfanyl-5-piperidin-1 ylmethyl-1H-indole-2-carboxylic acid amide, 5-(3-carbamoylpiperidin-1-ylmethyl)-3-phenylsulfanyl-1H-indole-2-carboxyl- ic acid amide, 3-phenylsulfanyl-5-(4-pyrimidin-2-yl-piperazin-1-ylmethyl)-1H-indole-2-ca- rboxylic acid amide, 5-[4-(3-phenylpropenyl)piperazin-1-ylmethyl]-3-phenylsulfanyl-1H-indole-2- -carboxylic acid amide, 4-(2-carbamoyl-3-phenylsulfanyl-1H-indol-5-ylmethyl)-[1,4]diazepane-1-car- boxylic acid tert-butyl ester, 5-[1,4]diazepan-1-ylmethyl-3-phenylsulfanyl-1H-indole-2-carboxylic acid amide, 5-(2-hydroxymethyl-pyrrolidin-1-ylmethyl)-3-phenylsulfanyl-1H-indo- le-2-carboxylic acid amide, 5-(1,4-dioxa-8-aza-spiro[4,5]dec-8-ylmethyl)-3-phenylsulfanyl-1H-indole-2- -carboxylic acid amide, and 5-[4-(4-fluorophenyl)piperazin-1-ylmethyl]-3-phenylsulfanyl-1H-indole-2-c- arboxylic acid amide. 14. The compound of formula II as recited in claim 7 wherein R.sub.8 is H, C.sub.1-C.sub.10alkyl, aryl(C.sub.1-C.sub.6alkyl), heterocycle(C.sub.1-C.sub.6alkyl) or C.sub.1-C.sub.6alkoxycarbonyl and R.sub.9 is H or heterocycle(C.sub.1-C.sub.6alkyl). 15. The compound of formula II as recited in claim 14 selected from the group consisting of: 6-aminomethyl-3-phenylsulfanyl-1H-indole-2-carboxylic acid amide, (2-carbamoyl-3-phenylsulfanyl-1H-indol-6-ylmethyl)-carbamic acid tert-butyl ester, 6-(benzylaminomethyl)-3-phenylsulfanyl-1H-indole-2-carboxylic acid amide, 6-[(4-nitrobenzylamino)methyl]-3-phenylsulfanyl-1H-indole-2-carboxylic acid amide, 6-[(4-dimethylaminobenzylamino)methyl]-3-phenylsulfanyl-1H-indole-2-carbo- xylic acid amide, 6-[(4-methylbenzylamino)methyl]-3-phenylsulfanyl-1H-indole-2-carboxylic acid amide, 6-[(4-methoxybenzylamino)methyl]-3-phenylsulfanyl-1H-indole-2-carboxylic acid amide, 6-[(4-bromobenzylamino)methyl]-3-phenylsulfanyl-1H-indole-2-carboxylic acid amide, 6-[(4-chlorobenzylamino)methyl]-3-phenylsulfanyl-1H-indole-2-carboxylic acid amide, 6-{[(biphenyl-4-ylmethyl)amino]methyl}-3-phenylsulfanyl-1H-indole-2-carbo- xylic acid amide, 6-[(3-nitrobenzylamino)methyl]-3-phenylsulfanyl-1H-indole-2-carboxylic acid amide, 6-[(2-nitrobenzylamino)methyl]-3-phenylsulfanyl-1H-indole-2-carboxylic acid amide, 3-phenylsulfanyl-6-[(4-trifluoromethylbenzylamino)methyl]-1H-indole-2-car- boxylic acid amide, 6-[(3-fluoro-5-trifluoromethylbenzylamino)methyl]-3-phenylsulfanyl-1H-ind- ole-2-carboxylic acid amide, 6-{[(2-methoxynaphthalen-1-ylmethyl)amino]-methyl]}-3-phenylsulfanyl-1H-i- ndole-2-carboxylic acid amide, 6-[(2,4-dimethoxybenzylamino)methyl]-3-phenylsulfanyl-1H-indole-2-carboxy- lic acid amide, 6-[(3-phenoxybenzylamino)methyl]-3-phenylsulfanyl-1H-indole-2-carboxylic acid amide, 6-[(3-methoxybenzylamino)methyl]-3-phenylsulfanyl-1H-indole-2-carboxylic acid amide, 6-[(2-methylbenzylamino)methyl]-3-phenylsulfanyl-1H-indole-2-carboxylic acid amide, 6-[(3-methylbenzylamino)methyl]-3-phenylsulfanyl-1H-indole-2-carboxylic acid amide, 6-[(2-fluoro-3-trifluoromethylbenzylamino)methyl]-3-phenylsulfanyl-1H-ind- ole-2-carboxylic acid amide, 6-[(2-methoxybenzylamino)methyl]-3-phenylsulfanyl-1H-indole-2-carboxylic acid amide, 6-{[(10-chloro-anthracen-9-ylmethyl)amino]methyl}-3-phenylsulfanyl-1H-ind- ole-2-carboxylic acid amide, 6-[(3,5-dichloro-2-hydroxybenzylamino)methyl]-1-phenylsulfanyl-1H-indole-- 2-carboxylic acid amide, 6-[(3-bromo-4,5-dimethoxybenzylamino)methyl]-3-phenylsulfanyl-1H-indole-2- -carboxylic acid amide, 6-[(4-benzyloxy-3-methoxybenzylamino)methyl]-3-phenylsulfanyl-1H-indole-2- -carboxylic acid amide, 6-[(3-benzyloxy-4-methoxybenzylamino)methyl]-3-phenylsulfanyl-1H-indole-2- -carboxylic acid amide, 6-{[(5-nitrothiophen-2-ylmethyl)amino]methyl}-3-phenylsulfanyl-1H-indole-- 2-carboxylic acid amide, 4-{[(2-carbamoyl-3-phenylsulfanyl-1H-indol-6-ylmethyl)amino]methyl}benzoi- c acid methyl ester, 3-phenylsulfanyl-6-[(4-styrylbenzylamino)methyl]-1H-indole-2-carboxylic acid amide, 6-[(2-fluoro-6-trifluoromethylbenzylamino)methyl]-3-phenylsulfanyl-1H-ind- ole-2-carboxylic acid amide, 6-({[5-(2-chlorophenyl)-furan-2-ylmethyl]amino}methyl)-3-phenylsulfanyl-1- H-indole-2-carboxylic acid amide, 6-{[(1-benzenesulfonyl-1H-pyrrol-2-ylmethyl)amino]methyl}-3-phenylsulfany- l-1H-indole-2-carboxylic acid amide, 6-{[bis-(5-nitrofuran-2-ylmethyl)amino]methyl}-3-phenylsulfanyl-1H-indole- -2-carboxylic acid amide, and 6-{[(5-nitrofuran-2-ylmethyl)amino]methyl}-3-phenylsulfanyl-1H-indole-2-c- arboxylic acid amide. 16. The compound of formula II as recited in claim 7 wherein R.sub.8 is P and R.sub.9 is H. 17. The compound of formula II as recited in claim 16 selected from the group consisting of: 6-[(2-aminopropionylamino)methyl]-3-phenylsulfanyl-1H-indole-2-carboxylic acid amide, 6-[(2-aminoacetylamino)methyl]-3-phenylsulfanyl-1H-indole-2-carboxylic acid amide, 6-[(2-amino-3-methylpentanoylamino)methyl]-3-phenylsulfanyl-1H-indole-2-c- arboxylic acid amide, 2-aminopentanedioic acid 5-amide 1-[(2-carbamoyl-3-phenylsulfanyl-1H-indol-6-ylmethyl)amide], 6-{[(2-amino-3-(1H-indol-3-yl)propionylamino]methyl}-3-phenylsulfanyl-1H-- indole-2-carboxylic acid amide, 6-[(2-amino-3-phenylpropionylamino)methyl]-3-phenylsulfanyl-1H-indole-2-c- arboxylic acid amide, 6-[(2-amino-4-methylsulfanylbutyrylamino)methyl]-3-phenylsulfanyl-1H-indo- le-2-carboxylic acid amide, 6-[(2,6-diaminohexanoylamino)methyl]-3-phenylsulfanyl-1H-indole-2-carboxy- lic acid amide, and 3-amino-N-(2-carbamoyl-3-phenylsulfanyl-1H-indol-6-ylmethyl)succinamic acid. 18. The compound of formula II as recited in claim 7 wherein R.sub.8 is aryl(C.sub.2-C.sub.6alkenyl), diaryl(C.sub.2-C.sub.6alkenyl) or heterocycle(C.sub.2-C.sub.6alkenyl) and R.sub.9 is H or heterocycle(C.sub.2-C.sub.6alkenyl). 19. The compound of formula II as recited in claim 18 selected from the group consisting of: 6-{[(bis-(3-furan-2-yl-allyl)amino]methyl}-3-phenylsulfanyl-1H-indole-2-c- arboxylic acid amide, 6-{[(3,3-diphenylallylamino]methyl}-3-phenylsulfanyl-1H-indole-2-carboxyl- ic acid amide, and 6-{[3-(4-hydroxy-3-methoxyphenyl)allylamino]methyl}-3-phenylsulfanyl-1H-i- ndole-2-carboxylic acid amide. 20. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound selected from the group consisting of formula I or formula II as recited claim 1, or a stereoisomer, an enantiomer, a racemate or a tautomer of said compound, or a pharmaceutically acceptable salt thereof. 21. A method for the preparation of a pharmaceutical composition useful for inhibiting casein kinase I.epsilon. activity comprising the formulation of a compound of formula I or formula II, or a stereoisomer, an enantiomer, a racemate or a tautomer of said compound, or a pharmaceutically acceptable salt thereof, in combination with one or more pharmaceutically acceptable carriers, diluents or excipients, ##STR00051## wherein X is S or S(O).sub.n; R.sub.1 is H or C.sub.1-C.sub.6alkyl; R.sub.2 is NR.sub.5R.sub.6; R.sub.3 is aryl or heterocycle; R.sub.4 is C.sub.1-C.sub.6alkyl or halogen; R.sub.5 is H or C.sub.1-C.sub.6alkyl; R.sub.6 is H or C.sub.1-C.sub.6alkyl; R.sub.7 is CH.sub.2NR.sub.8R.sub.9 wherein R.sub.8 is H, C.sub.1-C.sub.10alkyl, C.sub.3-C.sub.8cycloalkyl, aryl, aryl(C.sub.1-C.sub.6alkyl), aryl(C.sub.2-C.sub.6alkenyl), diaryl(C.sub.2-C.sub.6alkenyl), heterocycle, heterocycle(C.sub.1-C.sub.6alkyl), heterocycle(C.sub.2-C.sub.6alkenyl), hydroxy(C.sub.1-C.sub.6alkyl), dihydroxy(C.sub.2-C.sub.6alkyl), acyl, C.sub.1-C.sub.6alkoxycarbonyl, aryl(C.sub.1-C.sub.6alkoxy)carbonyl, carbamoyl(C.sub.1-C.sub.6alkyl), or P; R.sub.9 is H, C.sub.1-C.sub.10alkyl, heterocycle(C.sub.1-C.sub.6alkyl) or heterocycle(C.sub.2-C.sub.6alkenyl); or R.sub.8 and R.sub.9 together with the nitrogen to which they are attached form a heterocycle; and wherein P is Gly, or L- or D-Ala, Val, Leu, Ile, Ser, Cys, Thr, Met, Pro, Phe, Tyr, Trp, His, Lys, Arg, Asp, Gly, Asn or Gln; m is 0, 1 or 2; and n is 1 or 2. 22. The method of claim 21 wherein said inhibition of casein kinase I.epsilon. activity results in a lengthening of circadian rhythm period. 